Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ritlecitinib tosilate
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ritlecitinib tosilate is the tosilate salt form of **ritlecitinib**, an oral **small-molecule** covalent kinase inhibitor developed by **Pfizer**. It is designed to selectively inhibit **Janus kinase 3** and kinases of the **TEC family**, thereby modulating signaling downstream of common gamma-chain cytokine receptors and other immune pathways involved in lymphocyte activation and inflammatory disease. The marketed product **Litfulo** is approved for severe alopecia areata, while the compound has also been investigated in other immune-mediated disorders, including **hidradenitis suppurativa**, where Pfizer is running clinical development.
- Brand names
- Litfulo
- Other names
- ritlecitinib tosylateritlecitinib tosilate
02
Targets
TXKBMX (Bone Marrow Tyrosine Kinase X-linked)BTK (Bruton tyrosine kinase)JAK3 (Janus kinase 3)ITK (Interleukin 2-inducible T-cell kinase)
Beyond the preview
Go deeper on ritlecitinib tosilate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ritlecitinib tosilate.